Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Li Kang Biomedical Co's EBIT per Share for the
three
months ended in Mar. 2026 was NT$0.44.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$3.03.
During the past 12 months, the average EBIT per Share Growth Rate of Li Kang Biomedical Co was -4.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -14.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 3.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 4.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Li Kang Biomedical Co's EBIT per Share or its related term are showing as below:
ROCO:6242'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.6 Med: 15.9 Max: 93.7
Current: -14.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Li Kang Biomedical Co was 93.70% per year. The lowest was -14.60% per year. And the median was 15.90% per year.
ROCO:6242's 3-Year EBIT Growth Rate is ranked worse than 80.57% of 597
companies
in the Travel & Leisure industry
Industry Median: 10.6
vs ROCO:6242: -14.60
Li Kang Biomedical Co (ROCO:6242) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Li Kang Biomedical Co EBIT per Share Related Terms
Li Kang Biomedical Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Li Kang Biomedical Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Li Kang Biomedical Co (ROCO:6242) has a EBIT per Share of NT$3.03 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Li Kang Biomedical Co and its competitors. According to the industry distribution chart, Li Kang Biomedical Co ranks #481 out of 597 companies in the Travel & Leisure industry, placing it in the top 80.6%.
Is Li Kang Biomedical Co's EBIT per Share too high?
Li Kang Biomedical Co's current EBIT per Share is NT$3.03. Based on the distribution chart, Li Kang Biomedical Co ranks #481 out of 597 companies in the Travel & Leisure industry, which is in the bottom quartile relative to peers. Overall, Li Kang Biomedical Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Li Kang Biomedical Co's EBIT per Share compare to BKNG and ABNB?
According to the Travel & Leisure industry distribution chart, Li Kang Biomedical Co ranks #481 out of 597 companies for EBIT per Share. This places Li Kang Biomedical Co in the lower half of its industry. The industry median EBIT per Share is 10.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Travel & Leisure company?
The median EBIT per Share among Travel & Leisure companies is 10.60, based on 597 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Li Kang Biomedical Co and its competitors. For the Travel & Leisure industry, the median EBIT per Share is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Li Kang Biomedical Co's current EBIT per Share is NT$3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Li Kang Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Li Kang Biomedical Co (ROCO:6242) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.78, compared to a current price of NT$34.65 — trading 10.6% below its estimated fair value. The current EBIT per Share is NT$3.03. Li Kang Biomedical Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Li Kang Biomedical Co (ROCO:6242), the current EBIT per Share is NT$3.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Li Kang Biomedical Co (ROCO:6242) Overvalued in 2026?
Based on GuruFocus' analysis, Li Kang Biomedical Co stock appears to be undervalued.
The current stock price of NT$34.65 is trading 10.6% below its estimated GF Value™ of NT$38.78.
GuruFocus considers Li Kang Biomedical Co to be Modestly Undervalued.
Key valuation signals for ROCO:6242:
EBIT per Share: NT$3.03
GF Value™: NT$38.78 vs. price of NT$34.65 (10.6% below fair value)
No single metric tells the full story. See the ROCO:6242 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Li Kang Biomedical Co Ltd is a Taiwan based company engages in tourism factory businesses, telemarketing, as well as the manufacturing and sales of cosmetics and hygienic drinks.
81GF Score
Get the complete analysis for ROCO:6242
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6242 has been successfully added to your 
